Skip to content
PHARMACEUTICAL PREPARATIONS

Barinthus Biotherapeutics PLC. BRNS

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
▼ 100.0% YoY
$-66.4M
$-48.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -66.4
20M40M-30M-60M
202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -454.1% · Net -408.7%
-5000%-10000%-15000%
202020222025
ROE
FY2025 · ROE -65.0%
-20%-40%-60%
202020222025
Three returns, three denominators.

Each USD of equity lost 65 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -48.0
-20M-40M
202020222025

Total assetsUSD 98.2M
EquityUSD 74.2M
CashUSD 70.5M
Current ratio7.77×

Equity funds 76% of total assets.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BRNS, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.00.0
Operating income $B−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.10.0−0.0−0.0
Income tax $B−0.0−0.0−0.0−0.0−0.00.0
Net income $B−0.1−0.1−0.10.0−0.1−0.0
Free cash flow $B−0.0−0.0−0.1−0.0−0.0−0.0
EPS, diluted $−1.64−1.55−1.910.14−1.96−2.24
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−65.0−38.6−34.12.2——
Shares out B0.040.040.040.040.040.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 24 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onnot stated in the filings
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image